Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Share:
Related AGN
A Look At Dan Loeb's Diversified 13F
Paulson & Company's Q4 Moves: Healthcare And Beyond
Thanks For The Corporate Bond Bubble, Fed (Seeking Alpha)
Related VRX
Morgan Stanley Reiterates Overweight, Raises Price Target On Valeant Pharmaceuticals On New Proforma Model For SLXP
Here's Why CRT Capital Boosted Valeant Pharmaceuticals' Price Target
Today's Market: Pharma Mergers And Acquisitions Impacting These Stocks (Seeking Alpha)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General

 

Related Articles (AGN + VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters